402 filings
POS AM
SPRC
SciSparc Ltd
17 Jun 24
Prospectus update (post-effective amendment)
4:05pm
6-K
SPRC
SciSparc Ltd
14 Jun 24
Report of Foreign Private Issuer
4:00pm
6-K
SPRC
SciSparc Ltd
3 Jun 24
SciSparc Secures Strategic Advantage with Grant of European Patent
7:13am
POS AM
SPRC
SciSparc Ltd
2 May 24
Prospectus update (post-effective amendment)
5:17pm
425
SPRC
SciSparc Ltd
2 May 24
Business combination disclosure
4:46pm
6-K
SPRC
SciSparc Ltd
2 May 24
Consolidated Financial Statements as for Consolidated Financial Statements as for To the shareholders of
4:02pm
20-F/A
2023 FY
SPRC
SciSparc Ltd
2 May 24
Annual report (foreign) (amended)
9:18am
425
SPRC
SciSparc Ltd
12 Apr 24
Business combination disclosure
9:23am
6-K
SPRC
SciSparc Ltd
11 Apr 24
Agreement and Plan of Merger
4:05pm
S-8
SPRC
SciSparc Ltd
1 Apr 24
Registration of securities for employees
5:11pm
20-F
2023 FY
SPRC
SciSparc Ltd
Annual report (foreign)
1 Apr 24
5:03pm
6-K
SPRC
SciSparc Ltd
27 Mar 24
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
9:18am
6-K
SPRC
SciSparc Ltd
15 Mar 24
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
8:00am
6-K
SPRC
SciSparc Ltd
13 Mar 24
Report of Foreign Private Issuer
9:06am
6-K
SPRC
SciSparc Ltd
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
EFFECT
SPRC
SciSparc Ltd
7 Mar 24
Notice of effectiveness
12:15am
SC 13G
SPRC
SciSparc Ltd
6 Mar 24
SciSparc / YA II PN ownership change
5:02pm
6-K
SPRC
SciSparc Ltd
29 Feb 24
Report of Foreign Private Issuer
9:07am
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
6-K
SPRC
SciSparc Ltd
27 Feb 24
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
8:35am